Phialogics closes 600,000 € pre-seed financing round

Being able to rebalance the immune response in acute and chronic inflammation is key for many patients suffering from autoimmune diseases. Thanks to an innovative and patented technology, Phialogics brings a new answer to these unmet medical needs. Its strategy has the potential to provide new solutions for patients with autoimmune diseases by rebalancing their overactive immune response in selected organs and tissue.

The concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed tissue and/or disease-causing immune cells. 

Andreas Ernst, Co-Founder & CEO of Phialogics comments: “For 2023, our goals are to further develop our lead candidate, completing proof of concept in preclinical models and comparing our lead to the standard of care. In addition, as a part of our new discovery project, we will expand our portfolio to novel bi-specific immune checkpoint modulators. This becomes possible thanks to the HTGF financing round.”

Phialogics has been found in 2021 by a team of widely recognized experts in protein engineering and immunology based on research concepts established at the Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, and the Medical Faculty of the Goethe-University Frankfurt. In September 2022 Phialogics joined the BaseLaunch portfolio.

(Press release / SK)